OncShare

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #lungCancer Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito Horinouchi 🇯🇵 Biagio Ricciuti 🇺🇸 Eric Singhi 🇺🇸 Gil Morgan 🇺🇸 With our Distinguished OncoAlert 🚨Faculty Sanjay Popat 🇬🇧 Stephen Liu 🇺🇸 Charu Aggarwal 🇺🇸 GILBERTO de lima LOPES Junior 🇺🇸 Jarushka Naidoo 🇮🇪 1253O - Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours Presenter: Alexander Drilon 🇺🇸 Discussant: Jürgen Wolf 1256MO - Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours Presenter: Benjamin Besse 🇫🇷(France) Discussant: Adrianus Johannes De Langen LBA8 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways Presenter: Pascale Tomasini 🇫🇷 Discussant: Biagio Ricciuti LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected NSCLC Presenter: Glenwood Goss🇨🇦 Discussant: Pilar Garrido LBA54 - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced NSCLC after disease progression on osimertinib: 2nd interim OS from MARIPOSA-2 Presenter: Sanjay Popat 🇬🇧 Discussant: Jürgen Wolf 1241MO - Osimertinib after definitive chemoradiotherapy in unresectable stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study Presenter: Shun Lu 🇨🇳 Discussant: Heather Wakelee 1207MO - Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase II POTENTIAL study Presenter:Yasuhiro Tsutani 🇯🇵 Discussant: Heather Wakelee 1257MO - ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype non-squamous (NSQ) NSCLC Presenter: María de Miguel 🇪🇸 Discussant: Mariana Brandao LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma Presenter: Remon Jordi 🇫🇷 Discussant: Fiona Blackhall LBA52 - Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) NSCLC Presenter: David R. Spigel, MD 🇺🇸 Discussant: Marina Chiara Garassino Lung Christian Rolfo, MD, PhD, MBA,Dr.hc Narjust Florez M.D. Bartomeu Massuti Peters Solange Umberto Malapelle Christine M. Lovly, MD, PhD Fabrice Barlesi Jill Feldman Ben Solomon Raffaele Califano Terri Conneran #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps--Maléa  Emre Yekeduz Elisa Agostinetto Elisabetta Bonzano Eric Singhi Bárbara Vieira Lima Aguiar Melão Dr. Joseph McCollom DO Luca Arecco

Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients per tumour type were assessed for developing a screening tool for tumour-agnostic potential (i.e., the ESMO Tumour-Agnostic Classifier). #TumourAgnostic #PrecisionMedicine https://lnkd.in/evj22z_s

The August issue of Cancer Discovery is now online! The cover features work by Federica Pecci, Seshiru Nakazawa, Pasi Jänne, Mark Awad, and colleagues showing that activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer that is targetable with MET inhibitors: https://lnkd.in/e32A-kbX Also in this issue: lifileucel in patients with immune checkpoint inhibitor-resistant advanced NSCLC, novel WRN helicase inhibitors, the St. Jude Survivorship Portal and more - read it all here: https://lnkd.in/eUmJwBmE AACR Journals

🚨🥁ANNOUNCEMENT: Precision medicine & tumor-agnostic drug development take center stage ESMO - European Society for Medical Oncology #ESMO24 Annual Congress! ‼️👉Honored to be invited to speak at the SPECIAL ESMO & ASCO joint session in Barcelona, Spain on "Tumour-agnostic drug development" at the ESMO congress 2024. 👉Chaired jointly by the amazing ESMO President Dr. Andrés Cervantes andres cervantes and our incredible American Society of Clinical Oncology (ASCO) President Dr. Robin Zon join us for an exclusive session Prime time on Sunday "Novel Pathways for Development of Precision Therapeutics in Molecular Oncology." 🧬🎯 🗓️ 10:15 - 11:45 AM. 📍 Oviedo Auditorium - Hall 3 👉When : Sun, 15.09.2024 👉Our amazing Dr. Julie Gralow Chief Medical Officer American Society of Clinical Oncology (ASCO) will be talking about Regulatory sandboxes: How to synchronize safe, timely regulation with scientific breakthroughs in molecular ‘niches’ #genomics #AI #immunotherapy #PrecisionMedicine https://lnkd.in/eJXtYv3r

📢 𝐍𝐄𝐖 𝐒𝐓𝐔𝐃𝐘 published in the Nature Medecine by the lead author Peters Solange and her colleagues.   💡 Comprehensive biomarker testing is indispensable for patients with advanced non-small cell lung cancer (NSCLC) to determine the most effective treatment options. Liquid biopsies present a less invasive and more rapid alternative to traditional tissue biopsies, addressing challenges such as inadequate tissue samples. 🔬The BFAST trial is investigating the efficacy of targeted therapies for NSCLC identified through liquid biopsies. The study results indicated that 81.5% of patients with ROS1-positive NSCLC exhibited a positive response to the targeted therapy entrectinib. 🚀 These findings affirm that liquid biopsies are efficacious in guiding treatment decisions, offering a quicker and more patient-centric approach to cancer care. ↪ Full paper here: https://lnkd.in/e8K-Jmfb Shirish Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Chong-Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe June Assaf,Venice Archer, Rafal Dziadziuszko #CancerResearch #NSCLC #LiquidBiopsy #TargetedTherapy